Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H65A | ISIN: NL0010391025 | Ticker-Symbol: PHGN
Tradegate
02.09.25 | 19:16
1,201 Euro
-2,67 % -0,033
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMING GROUP NV Chart 1 Jahr
5-Tage-Chart
PHARMING GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,2021,22102.09.
1,2011,21802.09.

Aktuelle News zur PHARMING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBeat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus12
DiPharming Group N.V. - 6-K, Report of foreign issuer2
DiPharming Group names new finance head2
DiPharming Group N.V.: Pharming Group appoints Kenneth Lynard as Chief Financial Officer75Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer...
► Artikel lesen
20.08.Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy259Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 20.08.2025 / 16:37 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
04.08.Pharming Group N.V.: Pharming Group to participate in August investor conference384Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference...
► Artikel lesen
PHARMING Aktie jetzt für 0€ handeln
31.07.Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M9
31.07.Pharming Group N.V. - 6-K, Report of foreign issuer2
31.07.Pharming reports Q2 results2
31.07.Pharming Group N.V.: Pharming Group reports second quarter and first half 2025 financial results and provides business update519Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased...
► Artikel lesen
17.07.Pharming Group N.V.: Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31405Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second...
► Artikel lesen
24.06.Pharming Group N.V. - 6-K, Report of foreign issuer7
24.06.Pharming Group N.V.: Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis8
11.06.Pharming Group N.V. - 6-K, Report of foreign issuer11
11.06.Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders452Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM)...
► Artikel lesen
28.05.Pharming Group N.V.: Pharming Group to participate in June investor conferences473Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences...
► Artikel lesen
09.05.Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M3
08.05.Pharming Group N.V. - 6-K, Report of foreign issuer3
08.05.Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update654First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting...
► Artikel lesen
30.04.Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director5
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1